{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:04:51Z","timestamp":1791932691956,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03835-x","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T01:01:16Z","timestamp":1727917276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7383-071X","authenticated-orcid":false,"given":"Melissa","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingxue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Rivest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Boone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Noessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"4","key":"3835_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239\u2013252. https:\/\/doi.org\/10.1038\/nri3174","journal-title":"Nat Rev Immunol"},{"key":"3835_CR2","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S (2018) Natural killer cells: development, maturation, and clinical utilization. Front Immunol 9:1869. https:\/\/doi.org\/10.3389\/fimmu.2018.01869","journal-title":"Front Immunol"},{"key":"3835_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumorantitumour adoptive cell immunotherapy. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-022-00491-0","journal-title":"Nat Rev Cancer"},{"key":"3835_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/asheducation-2013.1.247","volume":"2013","author":"JS Miller","year":"2013","unstructured":"Miller JS (2013) Therapeutic applications: natural killer cells in the clinic. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2013:247\u2013253. https:\/\/doi.org\/10.1182\/asheducation-2013.1.247","journal-title":"Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program"},{"key":"3835_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00578","author":"K Rezvani","year":"2015","unstructured":"Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00578","journal-title":"Front Immunol"},{"issue":"3","key":"3835_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.42","volume":"49","author":"HJ Kwon","year":"2017","unstructured":"Kwon HJ, Kim N, Kim HS (2017) Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med 49(3):e311. https:\/\/doi.org\/10.1038\/emm.2017.42","journal-title":"Exp Mol Med"},{"issue":"19","key":"3835_CR7","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cells11193147","volume":"11","author":"A Mendoza-Valderrey","year":"2022","unstructured":"Mendoza-Valderrey A, Alvarez M, De Maria A, Margolin K, Melero I, Ascierto ML (2022) Next generation immuno-oncology strategies: unleashing nk cells activity. Cells 11(19):3147. https:\/\/doi.org\/10.3390\/cells11193147","journal-title":"Cells"},{"issue":"1","key":"3835_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL (2016) NK cells and cancer: You can teach innate cells new tricks. Nat Rev Cancer 16(1):7\u201319. https:\/\/doi.org\/10.1038\/nrc.2015.5","journal-title":"Nat Rev Cancer"},{"key":"3835_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575609","volume":"11","author":"H Alfarra","year":"2020","unstructured":"Alfarra H, Weir J, Grieve S, Reiman T (2020) Targeting NK Cell inhibitory receptors for precision multiple myeloma immunotherapy. Front Immunol 11:575609. https:\/\/doi.org\/10.3389\/fimmu.2020.575609","journal-title":"Front Immunol"},{"key":"3835_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896228","volume":"13","author":"A Ram\u00edrez-Labrada","year":"2022","unstructured":"Ram\u00edrez-Labrada A, Pesini C, Santiago L et al (2022) All About (NK Cell-Mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity. Front Immunol 13:896228. https:\/\/doi.org\/10.3389\/fimmu.2022.896228","journal-title":"Front Immunol"},{"issue":"3","key":"3835_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/ijms21030922","volume":"21","author":"R Molfetta","year":"2020","unstructured":"Molfetta R, Zitti B, Lecce M et al (2020) CD155: a multi-functional molecule in tumor progression. Int J Mol Sci 21(3):922. https:\/\/doi.org\/10.3390\/ijms21030922","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3835_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002128","volume":"9","author":"MY Lee","year":"2021","unstructured":"Lee MY, Robbins Y, Sievers C et al (2021) Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. J Immunother Cancer 9(3):e002128. https:\/\/doi.org\/10.1136\/jitc-2020-002128","journal-title":"J Immunother Cancer"},{"issue":"16","key":"3835_CR13","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.3390\/cancers13164129","volume":"13","author":"N Du","year":"2021","unstructured":"Du N, Guo F, Wang Y, Cui J (2021) NK cell therapy: a rising star in cancer treatment. Cancers 13(16):4129. https:\/\/doi.org\/10.3390\/cancers13164129","journal-title":"Cancers"},{"key":"3835_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3835_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C (2020) TIGIT as an emerging immune checkpoint. Clin Exp Immunol 200(2):108\u2013119. https:\/\/doi.org\/10.1111\/cei.13407","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"3835_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X et al (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19(7):723\u2013732. https:\/\/doi.org\/10.1038\/s41590-018-0132-0","journal-title":"Nat Immunol"},{"issue":"4","key":"3835_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004711","volume":"10","author":"EY Chiang","year":"2022","unstructured":"Chiang EY, Mellman I (2022) TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer 10(4):e004711. https:\/\/doi.org\/10.1136\/jitc-2022-004711","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3835_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.exphem.2005.07.006","volume":"33","author":"H Guven","year":"2005","unstructured":"Guven H, Konstantinidis KV, Alici E et al (2005) Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol 33(11):1320\u20131328. https:\/\/doi.org\/10.1016\/j.exphem.2005.07.006","journal-title":"Exp Hematol"},{"key":"3835_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-59745-409-4_10","volume":"506","author":"E Alici","year":"2009","unstructured":"Alici E, Sutlu T, Sirac DM (2009) Retroviral gene transfer into primary human natural killer cells. Methods Mol Biol Clifton NJ 506:127\u2013137. https:\/\/doi.org\/10.1007\/978-1-59745-409-4_10","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"3835_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00266","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW (2015) Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00266","journal-title":"Front Immunol"},{"issue":"10","key":"3835_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1089\/jop.2013.0148","volume":"29","author":"M Byrne","year":"2013","unstructured":"Byrne M, Tzekov R, Wang Y et al (2013) Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 29(10):855\u2013864. https:\/\/doi.org\/10.1089\/jop.2013.0148","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"3835_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.04.015","author":"MA Ligtenberg","year":"2018","unstructured":"Ligtenberg MA, Pico de Coa\u00f1a Y, Shmushkovich T et al (2018) Self-delivering RNAi targeting PD-1 improves tumor-specific T cell functionality for adoptive cell therapy of malignant melanoma. Mol Ther J Am Soc Gene Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.015","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"1","key":"3835_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/nar\/gkw1005","volume":"45","author":"S Ly","year":"2017","unstructured":"Ly S, Navaroli DM, Didiot MC et al (2017) Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res 45(1):15\u201325. https:\/\/doi.org\/10.1093\/nar\/gkw1005","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3835_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jin2.63","volume":"4","author":"IM Adjei","year":"2019","unstructured":"Adjei IM, Jordan J, Tu N et al (2019) Functional recovery of natural killer cell activity by nanoparticle-mediated delivery of transforming growth factor beta 2 small interfering RNA. J Interdiscip Nanomedicine 4(4):98\u2013112. https:\/\/doi.org\/10.1002\/jin2.63","journal-title":"J Interdiscip Nanomedicine"},{"issue":"4","key":"3835_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/nano7040077","volume":"7","author":"K Tatiparti","year":"2017","unstructured":"Tatiparti K, Sau S, Kashaw SK, Iyer AK (2017) siRNA delivery strategies: a comprehensive review of recent developments. Nanomater Basel Switz 7(4):77. https:\/\/doi.org\/10.3390\/nano7040077","journal-title":"Nanomater Basel Switz"},{"issue":"9","key":"3835_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/biomedicines9091277","volume":"9","author":"A Rotte","year":"2021","unstructured":"Rotte A, Sahasranaman S, Budha N (2021) Targeting TIGIT for immunotherapy of cancer: update on clinical development. Biomedicines 9(9):1277. https:\/\/doi.org\/10.3390\/biomedicines9091277","journal-title":"Biomedicines"},{"key":"3835_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3389\/fimmu.2020.00812","volume":"11","author":"A Pfefferle","year":"2020","unstructured":"Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ (2020) Deciphering natural killer cell homeostasis. Front Immunol 11:812. https:\/\/doi.org\/10.3389\/fimmu.2020.00812","journal-title":"Front Immunol"},{"key":"3835_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.114","volume":"47","author":"SR Yoon","year":"2015","unstructured":"Yoon SR, Kim TD, Choi I (2015) Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med 47:e141. https:\/\/doi.org\/10.1038\/emm.2014.114","journal-title":"Exp Mol Med"},{"issue":"1","key":"3835_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","volume":"21","author":"MF Rasul","year":"2022","unstructured":"Rasul MF, Hussen BM, Salihi A et al (2022) Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy. Mol Cancer 21(1):64. https:\/\/doi.org\/10.1186\/s12943-021-01487-4","journal-title":"Mol Cancer"},{"issue":"9","key":"3835_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.2673","volume":"31","author":"V Pattanayak","year":"2013","unstructured":"Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR (2013) High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31(9):839\u2013843. https:\/\/doi.org\/10.1038\/nbt.2673","journal-title":"Nat Biotechnol"},{"key":"3835_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1479-5876-11-30","volume":"11","author":"D Fruci","year":"2013","unstructured":"Fruci D, Lo Monaco E, Cifaldi L et al (2013) T and NK cells: two sides of tumor immunoevasion. J Transl Med 11:30. https:\/\/doi.org\/10.1186\/1479-5876-11-30","journal-title":"J Transl Med"},{"key":"3835_CR32","doi-asserted-by":"publisher","first-page":"1269614","DOI":"10.3389\/fimmu.2023.1269614","volume":"14","author":"S Nersesian","year":"2023","unstructured":"Nersesian S, Carter EB, Lee SN, Westhaver LP, Boudreau JE (2023) Killer instincts: natural killer cells as multifactorial cancer immunotherapy. Front Immunol 14:1269614. https:\/\/doi.org\/10.3389\/fimmu.2023.1269614","journal-title":"Front Immunol"},{"key":"3835_CR33","doi-asserted-by":"publisher","first-page":"1275028","DOI":"10.3389\/fimmu.2023.1275028","volume":"14","author":"H Jiang","year":"2023","unstructured":"Jiang H, Jiang J (2023) Balancing act: the complex role of NK cells in immune regulation. Front Immunol 14:1275028. https:\/\/doi.org\/10.3389\/fimmu.2023.1275028","journal-title":"Front Immunol"},{"key":"3835_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-021-02120-z","author":"M Vogler","year":"2021","unstructured":"Vogler M, Shanmugalingam S, S\u00e4rchen V et al (2021) Unleashing the power of NK cells in anticancer immunotherapy. J Mol Med Berl Ger. https:\/\/doi.org\/10.1007\/s00109-021-02120-z","journal-title":"J Mol Med Berl Ger"},{"issue":"3","key":"3835_CR35","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028480","volume":"11","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Schreiber RD (2019) Interferon \u03b3 and Its Important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol 11(3):a028480. https:\/\/doi.org\/10.1101\/cshperspect.a028480","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"3835_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi M, Li T, Niu M et al (2023) Exploiting innate immunity for cancer immunotherapy. Mol Cancer 22(1):187. https:\/\/doi.org\/10.1186\/s12943-023-01885-w","journal-title":"Mol Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03835-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03835-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T12:03:53Z","timestamp":1731758633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03835-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03835-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"239"}}